Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00147537 · ClinicalTrials.gov registry record · Phase 1
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
NCT00147537: Completed Phase 1 study, sponsored by Pfizer.
NCT00147537 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 282 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (370% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00147537, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
Study Summary
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Primary Outcome
The maximum tolerated dose of CP-751,871 in combination with paclitaxel and carboplatin is the highest dose level below the Maximum Administered Dose (the dose level at which 2 or more out of 3 to 6 patients experience a Dose Limiting Toxicity at a dose level in Cycle 1) at which none or one out of 6 patients experience a Cycle 1 Dose Limiting Toxicity.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG CP-751,871
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2005-02 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
What the finished NCT00147537 record still lists
NCT00147537 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (370% higher).
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT00147537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00147537 about?
NCT00147537 is a clinical study titled "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer". Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, ...
What is the current status of trial NCT00147537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2005-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00147537?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), CP-751,871 (DRUG).
Who is sponsoring clinical trial NCT00147537?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00147537's enrollment target sits among peer trials
282 139th of 2000 higher than 1,861 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia